We have located links that may give you full text access.
Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian stakeholders.
Expert Review of Pharmacoeconomics & Outcomes Research 2018 September 14
INTRODUCTION: Health Technologies Assessment requires that evidence about clinical, economic, social, and organizational aspects be considered and weighted in the selection of drugs for reimbursement. We investigate how evidence is balanced by committee members in Canada, where neither explicit weighing schemes nor thresholds are provided.
METHODS: Thirty-six past and present members of cancer drug appraisal committees participated in an online stated preferences experiment. The experiment included a ranking of drug attributes, a discrete choice experiment asking to vote in favor or against the funding of drugs described using five attributes, and a best-worst scaling experiment using the same drug descriptions.
RESULTS: Respondents focused on the clinical attributes of drugs, particularly on the survival benefit relative to a comparator. As a second criterion, respondents either consider economic attributes or they consider patient relevant attributes, depending on how questions are framed. The small sample size is a limitation to generalizability.
CONCLUSION: Understanding how individuals involved in HTA weigh evidence is important to the development of policy guidelines for the drug selection process. Our pilot results suggest that non-clinical criteria can become marginalized in the appraisal process in the absence of clear guidelines to their use. Avenues for further research are discussed.
METHODS: Thirty-six past and present members of cancer drug appraisal committees participated in an online stated preferences experiment. The experiment included a ranking of drug attributes, a discrete choice experiment asking to vote in favor or against the funding of drugs described using five attributes, and a best-worst scaling experiment using the same drug descriptions.
RESULTS: Respondents focused on the clinical attributes of drugs, particularly on the survival benefit relative to a comparator. As a second criterion, respondents either consider economic attributes or they consider patient relevant attributes, depending on how questions are framed. The small sample size is a limitation to generalizability.
CONCLUSION: Understanding how individuals involved in HTA weigh evidence is important to the development of policy guidelines for the drug selection process. Our pilot results suggest that non-clinical criteria can become marginalized in the appraisal process in the absence of clear guidelines to their use. Avenues for further research are discussed.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app